Liposomal-Encapsulated Doxorubicin (Myocet™; D-99) and Vinorelbine in Previously Treated Metastatic Breast Cancer Patients: A Feasibility Study

Abstract

Aims and background We conducted a feasibility study to determine the safety and efficacy of liposome-encapsulated doxorubicin (Myocet) and vinorelbine in previously treated metastatic breast cancer patients. Patients and methods Liposome-encapsulated doxorubicin (30 mg/m2) plus vinorelbine (25 mg/m2) on days 1 and 8, every 3 weeks were given until disease progression, sever toxicity or up to 9 cycles. All patients underwent tumor assessment before enrollment. Patients with a life expectancy longer than 3 months and measurable or assessable disease were eligible. Results Twenty-one patients were included. Median number of treatment cycles was 5 (range, 3–9). No complete response was obtained. Stable disease and/or partial response was obtained in 9 patients. Fifteen patients experienced grade 3–4 leukopenia. There was no significant decline in cardiac function. Non-hematological toxicity was tolerable (grade 1–2). Conclusions The association of doxorubicin and vinorelbine has been shown to be feasible in previously treated advanced breast cancer patients. Its efficacy should be tested as first-line therapy in metastatic patients with cardiac co-morbidities.